Payment overview · 2025
General Payments
$700.25
34 reported records · 16 companies
Healthcare provider profile · identity verified
David James Carty, MD
Allopathic & Osteopathic Physicians|Internal Medicine · POWAY, CA · NPI 1205802568
Verified facts
What the public records show
CMS Open Payments records show David James Carty, MD received $700.25 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.15 | 23.2% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.50 | 7.5% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $51.75 | 7.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.66 | 7.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.04 | 6.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.96 | 6.4% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $44.65 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.32 | 5.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.41 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.35 | 5.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.59 | 4.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.03 | 3.9% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $23.81 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.20 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.13 | 3.0% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $10.70 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $700.25 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.94 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.94 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.68 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.94 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $52.50 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $52.50 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $51.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $44.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.41 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $29.59 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $10.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 178 |
| Losartan Potassium | Losartan Potassium | 537 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 125 |
| Lisinopril | Lisinopril | 243 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 74 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 229 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 71 |
| Simvastatin | Simvastatin | 203 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 50 |
| Metformin Hcl | Metformin Hcl | 168 | 54 |
| Gabapentin | Gabapentin | 165 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 60 |
| Omeprazole | Omeprazole | 159 | 46 |
| Trazodone Hcl | Trazodone Hcl | 154 | 46 |
| Furosemide | Furosemide | 123 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 38 |
| Alprazolam | Alprazolam | 119 | 43 |
| Tramadol Hcl | Tramadol Hcl | 119 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 37 |
| Ozempic | Semaglutide | 91 | 16 |
| Alendronate Sodium | Alendronate Sodium | 88 | 24 |
| Lorazepam | Lorazepam | 86 | 31 |
| Finasteride | Finasteride | 85 | 25 |
| Ibuprofen | Ibuprofen | 84 | 27 |
| Glipizide | Glipizide | 77 | 20 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Donepezil Hcl | Donepezil Hcl | 75 | 18 |
| Lovastatin | Lovastatin | 73 | 20 |
| Eliquis | Apixaban | 71 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 23 |
| Benazepril Hcl | Benazepril Hcl | 69 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 14 |
| Azithromycin | Azithromycin | 64 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 16 |
| Carvedilol | Carvedilol | 58 | 20 |
| Allopurinol | Allopurinol | 54 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 21 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 33 |
| Hydrocortisone | Hydrocortisone | 42 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 11 |
| Atenolol | Atenolol | 40 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 19 |
| Mupirocin | Mupirocin | 36 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 13 |
| Valsartan | Valsartan | 35 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 34 | 34 |
| Meloxicam | Meloxicam | 34 | 15 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Prednisone | Prednisone | 29 | 16 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 25 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 14 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 13 |
| Jardiance | Empagliflozin | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Haloperidol | Haloperidol | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Diazepam | Diazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $700.25 · 34 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, APTIMA, BARRIGEL, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, GVOKE HYPOPEN, General - Pain Management, JARDIANCE, JYNARQUE, KISUNLA, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, SHINGRIX, Wegovy, bio-ConneKt | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error